Published in Br J Cancer on February 01, 1995
Targeted therapy in non-small-cell lung cancer--is it becoming a reality? Nat Rev Clin Oncol (2010) 2.26
Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br J Cancer (2004) 1.69
Lung cancer: Biology and treatment options. Biochim Biophys Acta (2015) 1.02
Clinical benefit from palliative chemotherapy in non-small-cell lung cancer extends to the elderly and those with poor prognostic factors. Br J Cancer (1998) 0.98
A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma. Br J Cancer (2000) 0.92
Use of chemotherapy at the end of life in a Portuguese oncology center. Support Care Cancer (2007) 0.91
Pre-operative chemotherapy in early stage resectable non-small-cell lung cancer: a randomized feasibility study justifying a multicentre phase III trial. Br J Cancer (1999) 0.88
Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: no evidence of increased efficacy. Br J Cancer (1997) 0.88
Chemotherapy for cancer patients who present late. BMJ (2004) 0.83
How should cancer presenting as a malignant pleural effusion be managed? Br J Cancer (1996) 0.83
A pilot study of mitomycin, cisplatin and continuous infusion 5-fluorouracil (MCF) in advanced non-small-cell lung cancer. Br J Cancer (1995) 0.79
A pilot study of MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in small-cell lung cancer. Br J Cancer (1998) 0.78
Cisplatin plus gemcitabine on days 1 and 4 every 21 days for solid tumors: result of a dose-intensity study. Invest New Drugs (2007) 0.78
Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic. Oncologist (2011) 0.77
Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer. Br J Cancer (2005) 0.77
Management of lung cancer. Qual Health Care (1998) 0.75
Palliative care--an essential component of cancer control. CMAJ (1998) 0.75
Lung cancer. 4: chemotherapy for non-small cell lung cancer: the end of the beginning. Thorax (2003) 0.75
Anticancer therapies in specialized palliative care--a multicenter survey. Support Care Cancer (2011) 0.75
Reporting results of cancer treatment. Cancer (1981) 28.83
Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet (1993) 6.08
A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med (1990) 4.66
Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst (1991) 4.24
Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial. J Clin Oncol (1988) 2.91
Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. A randomized, phase III trial. Ann Intern Med (1991) 2.37
Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules. Ann Intern Med (1981) 1.97
Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small-cell lung cancer. J Natl Cancer Inst (1993) 1.89
Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. J Clin Oncol (1990) 1.88
Mitomycin, ifosfamide and cis-platin in non-small cell lung cancer: treatment good enough to compare. Br J Cancer (1988) 1.64
Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference? Cancer (1989) 1.61
Benefits of polychemotherapy in advanced non-small-cell bronchogenic carcinoma. Cancer (1982) 1.28
A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. Br J Cancer (1990) 1.28
Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cisplatin) in advanced non-small cell lung cancer. Br J Cancer (1989) 1.20
Randomized comparison of two combination regimens versus minimal chemotherapy in nonsmall-cell lung cancer: a Southeastern Cancer Study Group Trial. J Clin Oncol (1990) 1.19
A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol (1986) 1.11
Symptomatic treatment versus combination chemotherapy for patients with extensive non-small cell lung cancer. Cancer (1991) 1.11
A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma. J Clin Oncol (1986) 1.02
Chemotherapy of advanced non-small-cell lung cancer with cyclophosphamide, adriamycin, methotrexate, and procarbazine versus cisplatin and etoposide. A randomized study. Am J Clin Oncol (1988) 0.90
Patterns of mediastinal metastases in bronchogenic carcinoma. Chest (1986) 0.85
Cisplatin and vindesine combination chemotherapy for non-small cell lung cancer: a randomized trial comparing two dosages of cisplatin. Jpn J Cancer Res (1986) 0.84
Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet (1994) 4.03
Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer. Lancet (1980) 2.82
In vitro and in vivo radiosensitivity of human tumour cells obtained from a pancreatic carcinoma xenograft. Nature (1976) 2.77
Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol (1982) 2.50
Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol (2008) 2.46
Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol (2006) 2.40
Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol (1999) 2.32
Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee. J Natl Cancer Inst (1993) 2.22
A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol (1998) 2.18
A comparison of children affected by prenatal alcohol exposure and attention deficit, hyperactivity disorder. Alcohol Clin Exp Res (1997) 2.13
A colony-forming assay for human tumour xenografts using agar in diffusion chambers. Br J Cancer (1976) 2.11
Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res (1995) 2.05
Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer (2004) 1.87
Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol (1995) 1.87
A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer (1989) 1.78
Development and evaluation of a PCR-based immunoassay for the rapid detection of methicillin-resistant Staphylococcus aureus. J Med Microbiol (1998) 1.76
Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy. Br J Cancer (2005) 1.71
Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br J Cancer (2004) 1.69
Palliative chemotherapy for advanced non-small cell lung cancer. BMJ (1994) 1.67
Radiotherapy improves the outlook for patients older than 1 year with Pediatric Oncology Group stage C neuroblastoma. J Clin Oncol (1991) 1.66
Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol (2001) 1.62
Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol (2001) 1.61
Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival. Ann Oncol (2005) 1.59
Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2). Ann Oncol (2005) 1.58
Cisplatin and its analogues in the treatment of advanced breast cancer: a review. Br J Cancer (1992) 1.56
Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC Lung Cancer Cooperative Group. Eur J Cancer (1997) 1.52
Prognostic factors in small cell lung cancer: a simple prognostic index is better than conventional staging. Eur J Cancer Clin Oncol (1987) 1.51
Breast cancer in adolescents and young women. Eur J Cancer (2003) 1.49
Factors contributing to the time taken to consult with symptoms of lung cancer: a cross-sectional study. Thorax (2008) 1.49
Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration. Lancet (1994) 1.49
Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques. Br J Cancer (2005) 1.48
Prevention of breast cancer with tamoxifen--an update on the Royal Marsden Hospital pilot programme. Eur J Cancer (1990) 1.47
Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer. J Clin Oncol (1987) 1.47
Response to specific anti-oestrogen (ICI182780) in tamoxifen-resistant breast cancer. Lancet (1995) 1.47
Growth of human tumour cell colonies from biopsies using two soft-agar techniques. Br J Cancer (1978) 1.46
Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer (2000) 1.45
Prognostic value of angiogenesis in operable non-small cell lung cancer. J Pathol (1996) 1.42
Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women. J Clin Endocrinol Metab (1993) 1.41
New treatments for advanced cancer: an approach to prioritization. Br J Cancer (2000) 1.41
Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). Ann Oncol (2009) 1.40
Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Res Treat (1998) 1.39
Mitomycin C, vinblastine and carboplatin: effective outpatient chemotherapy for advanced non-small cell carcinoma of the lung (NSCLC). Clin Oncol (R Coll Radiol) (2001) 1.39
Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma. Lancet (1980) 1.38
Effects of prenatal alcohol exposure at school age. I. Physical and cognitive development. Neurotoxicol Teratol (1991) 1.37
Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer. Eur J Cancer Clin Oncol (1984) 1.34
Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial. Br Med J (Clin Res Ed) (1981) 1.33
Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. Clin Cancer Res (1999) 1.32
Preoperative chemotherapy induces apoptosis in early breast cancer. Lancet (1997) 1.31
In vitro radiation response of cells from four human tumors propagated in immune-suppressed mice. Cancer Res (1978) 1.31
Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase. Br J Cancer (1995) 1.30
Aminoglutethimide in treatment of metastatic breast carcinoma. Lancet (1978) 1.27
Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurements and a report of localized 31P measurements of response to treatment. NMR Biomed (1998) 1.27
Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer. J Clin Endocrinol Metab (1982) 1.25
Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer. Br J Cancer (1997) 1.25
Aminoglutethimide dose and hormone suppression in advanced breast cancer. Eur J Cancer Clin Oncol (1983) 1.25
Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents. Br J Cancer (2003) 1.25
The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res Treat (1994) 1.24
Hypofractionated stereotactic radiotherapy in the management of recurrent glioma. Int J Radiat Oncol Biol Phys (1997) 1.23
Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. Br J Cancer (1993) 1.22
Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cisplatin) in advanced non-small cell lung cancer. Br J Cancer (1989) 1.20
Potential role of bcl-2 as a suppressor of tumour angiogenesis in non-small-cell lung cancer. Int J Cancer (1997) 1.19
Three years' experience with Ch1VPP (a combination of drugs of low toxicity) for the treatment of Hodgkin's disease. Br J Cancer (1979) 1.19
Health-related quality of life in narcolepsy. J Sleep Res (2001) 1.18
Effects of prenatal alcohol exposure at school age. II. Attention and behavior. Neurotoxicol Teratol (1991) 1.18
Reasons given by patients for participating, or not, in Phase 1 cancer trials. Eur J Cancer (2011) 1.18
Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer. Br J Cancer (2003) 1.18
In-vivo 31P magnetic resonance spectroscopy for monitoring treatment response in breast cancer. Lancet (1989) 1.18
Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res (1997) 1.17
Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. Ann Oncol (1998) 1.16
Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients. Clin Cancer Res (2000) 1.16
Autocrine function for insulin-like growth factor I in human small cell lung cancer cell lines and fresh tumor cells. Cancer Res (1990) 1.15
Chemotherapy of human breast-carcinoma xenografts. Br J Cancer (1980) 1.15
Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer. Br J Cancer (1983) 1.15
Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer (2000) 1.13
In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res (1995) 1.12
The pathway study: results of a pilot feasibility study in patients suspected of having lung carcinoma investigated in a conventional chest clinic setting compared to a centralised two-stop pathway. Lung Cancer (2003) 1.10
Symptomatic hypocalcaemia after treatment with high-dose aminohydroxypropylidene diphosphonate. Lancet (1987) 1.09
Mammography in the assessment of response to medical treatment of large primary breast cancer. Clin Radiol (1993) 1.09
Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin Cancer Res (1999) 1.09
A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. Clin Cancer Res (2000) 1.08
Primary medical (neo-adjuvant) chemotherapy for operable breast cancer. Eur J Cancer (1993) 1.08
Identifying high-risk pregnant drinkers: biological and behavioral correlates of continuous heavy drinking during pregnancy. J Stud Alcohol (1987) 1.07
Detection of viruses and body fluids which may contain viruses in the domestic environment. Epidemiol Infect (1998) 1.07
Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res (1997) 1.07
Modulation of Bcl-2 and Ki-67 expression in oestrogen receptor-positive human breast cancer by tamoxifen. Eur J Cancer (1994) 1.06
Mortality within 30 days of chemotherapy: a clinical governance benchmarking issue for oncology patients. Br J Cancer (2006) 1.06
Mesenteric desmoid tumours in Gardner's syndrome--review of medical treatments. Postgrad Med J (1989) 1.06
Cytological evaluation of biological prognostic markers from primary breast carcinomas. Breast Cancer Res Treat (1997) 1.06
Evaluation of the potential of diffusion-weighted imaging in prostate cancer detection. Acta Radiol (2007) 1.06
Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. Cancer Res (1993) 1.06
Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active new regimen. J Clin Oncol (1994) 1.06
The footballer's fracture. Br J Sports Med (1996) 1.05
Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma. Br J Cancer (2006) 1.05